
|Articles|May 7, 2019
Tufts CSDD: Adoption of AI is High Across Industry
Advertisement
The Tufts Center for Drug Development found in a recent analysis that the pharmaceutical industry is adopting artificial intelligence (AI) in numerous ways. 59% of respondents said they plan to expand artificial intelligence staff through 2020. The highest uses of AI are in clinical operations, safety/risk management, and information technology.
For more from the report, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
2
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
3
ACT Brief: Real-Time Trial Infrastructure Gaps, Built-In Data Security, and AI-Enabled CDMO Value
4
Real-Time Clinical Trials: What the FDA's Push Toward Continuous Oversight Means for Sponsors
5




